July 19, 2021 7:44am

The indexes have been pulling back, especially the Nasdaq while alternative indicators are sending more-negative signals, from declining market breadth as cell and gene therapy stocks continue under pressure

Pre-open indications: 1 BUY: MESO; 8 SELLs: BLUE, CRSP, EDIT, GBT, NTLA, CLLS, VCEL, VSTM; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

I challenge the status quo to achieve what most believe is impossible, each session breaking down tactical ways to earn

Dow futures are DOWN -1.28% (-444 points), S&P futures are DOWN -1.07% (-46 point) and NASDAQ futures are DOWN -0.86% (-126 points)

 

U.S. stock index futures fell on Monday on concern of increasing Covid-19 cases,

European stocks moved sharply lower as markets processed the latest OPEC oil production scenario and also with surges in Covid-19 cases,

  • international benchmark Brent crude futures slipped 1.35%% to $72.60 per barrel. U.S. crude futures also declined 1.41% to $70.80 per barrel.

Asia-Pacific stocks slipped, as oil prices fell after OPEC and its allies reached a deal.

 

Data Docket: National Association of Home Builders will release its latest survey results, giving consumers a glimpse into sentiment across the housing market. Economists expect the reading to be unchanged from the prior month at 81. Anything above 50 is considered positive sentiment.

 

Henry’omics:

Stock market woes expand and became more obvious as last week wore on…

After a turbulent week of trading, fostered by two days of congressional testimony from Fed Chair Powell and a trove of key economic reports.

The Dow fell 0.5%, the S&P 500 index sank 1% as the Nasdaq composite slumped 1.9%, though the Nasdaq 100 only gave up 0.9% last week; while the small-cap Russell 2000 tumbled 5.05%.

 

Friday’s evening’s recap: “weakness stimulates fluctuations in sector performance. The Advance/Decline (A/D) lines validate a sinking sentiment yet, again” …   https://www.regmedinvestors.com/articles/12005

  • The Nasdaq closed DOWN -115.90 points (-0.80%);
  • The IBB closed up +0.90% and XBI closed flat 0.00%;
  • Sector volume was LOW with 3 of the 14-upside having higher than the 3-month average volume with very LOW volume of 0 of 20-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +1.44 points or +8.47% at 18.45;
  • Friday’s percentage (%) of the 14-upside were +0.27% (AGTC) to +3.44% (CLLS) while the 20-downside ranges from -0.10% (SGMO) to -6.06% (PSTI);

Q3/21: 3 positive and 8 negative close

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?

Biostage (BSTG) closed up +$0.01 to $1.71 with 307 shares traded after Thursday’s -$0.01 to $1.70 with 1,596 shares traded, Wednesday’s +$0.06 to $1.71 with 996 shares traded, Tuesday’s +$0.14 to $1.64 with 1,100 shares traded and last Monday’s flat with 2,600 shares traded.

Question#1: WHAT happens to the future of the company … IF they can NOT exercise the warrants – they are “BROKE” if they do exercise – won’t they will be just “BROKE” in six (6) months?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

SELL:

bluebird bio (BLUE) closed down again -$0.75 to $26.78 after Thursday’s -$0.23 to $27.53, Wednesday’s-$1.10 to $27.76, Tuesday’s $28.86 and last Monday’s $29.79 with a negative -$0.28 or -1.05% pre-market indication.

CRISPR therapeutics (CRSP) closed down -$0.85 to $126.25 and has a negative -$1.76 or -1.39% pre-market indication.

Editas Medicine (EDIT) closed up +$0.40 to $42.39 after Thursday’s -$0.72 to $43.08, with a negative -$1.77 or -4.18% pre-market indication.

Global Blood Therapeutics (GBT) closed down -$0.86 to $31.97 and has a negative -$0.67 or -2.10% pre-market indication.

Intellia Therapeutics (NTLA) closed down again -$2.85 to $135.25 after Thursday’s -$2.96 to $138.10, Wednesday’s -$2.26 to $141.06 and has a negative -$3.24 or -2.37% pre-market indication.

Cellectis SA (CLLS) closed up +$0.47 to $14.15 after Thursday’s -$0.26 to $13.68 and last Wednesday’s -$0.80 to $13.94 and has a negative -0.53 or -3.57% pre-market indication.

Vericel (VCEL) closed down -$1.46 to $50.69 after Thursday’s $52.15, Wednesday’s $52.03  and last Tuesday’s $53.57 and the previous Monday’s $53.93 and has a negative -$0.19 or -0.37% pre-market indication.

Verastem (VSTM) closed down -$0.04 to $0.04 to $3.49 with a negative -$0.04 or -1.15% after news of a convert of $ 28 million aggregate principal of 2020 5.00% Convertible Senior Notes due 2048 (the 2020 Notes) in exchange for approximately 8.6 million shares of common stock, based on the existing Mandatory Conversion right.

 

BUY from SELL:

Mesoblast (MESO) closed down again -$0.39 to $7.01 after Thursday’s -$0.16 to $7.40 with a positive +$0.34 or +4.85% after news of COVID-19 ARDS trial results showed that two doses of remestemcel-L at days 3-5 conferred durable survival benefit through at least 90 days in the pre-specified subgroup of patients under age 65. Previously, in another view the trial did not meet its endpoint of 43% reduction in overall mortality,

 

The BOTTOM LINE: Another session of “any which way” works … I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

 It takes courage to not being discouraged by “our” universe of cell and gene therapy equities or sector.

My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

Q2 earnings LPS (loss-per-share) release date are soon to be divulged and not positively.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.